INT226172

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.52
First Reported 2007
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 6
Disease Relevance 1.56
Pain Relevance 0.31

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (Fbxo32)
Anatomy Link Frequency
skeletal muscles 2
muscle 1
nucleus 1
Fbxo32 (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 28 82.80 Quite High
cytokine 26 61.80 Quite High
anesthesia 4 5.00 Very Low Very Low Very Low
Inflammatory mediators 4 5.00 Very Low Very Low Very Low
isoflurane 4 5.00 Very Low Very Low Very Low
fibrosis 2 5.00 Very Low Very Low Very Low
Inflammatory marker 2 5.00 Very Low Very Low Very Low
Pain 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Stress 50 85.04 High High
INFLAMMATION 34 82.80 Quite High
Muscular Atrophy 28 76.72 Quite High
Insulin Resistance 18 75.48 Quite High
Acidosis 12 74.40 Quite High
Chronic Renal Failure 56 68.88 Quite High
Frailty 114 66.88 Quite High
Necrosis 2 59.88 Quite High
Cancer 10 59.52 Quite High
Appetite Loss 62 38.40 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
GSNO effectively blocked MAFbx/atrogin-1 mRNA expression induced by LPS (Fig. 5A and 5B) and promoted iNos mRNA expression both with and without LPS injection (Fig. 5C and 5D).
Transcription (expression) of MAFbx
1) Confidence 0.52 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2361191 Disease Relevance 0.14 Pain Relevance 0.03
This analysis was performed as described [12] to measure MAFbx/atrogin-1, MuRF1, iNos, superoxide dismutases (Sod-1, Sod-2, Sod-3) and catalase (Cat) mRNA expression in skeletal muscles and in cultured C2C12 myoblasts.
Transcription (expression) of atrogin-1 in skeletal muscles
2) Confidence 0.52 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2361191 Disease Relevance 0 Pain Relevance 0
This analysis was performed as described [12] to measure MAFbx/atrogin-1, MuRF1, iNos, superoxide dismutases (Sod-1, Sod-2, Sod-3) and catalase (Cat) mRNA expression in skeletal muscles and in cultured C2C12 myoblasts.
Transcription (expression) of MAFbx in skeletal muscles
3) Confidence 0.52 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2361191 Disease Relevance 0 Pain Relevance 0
GSNO effectively blocked MAFbx/atrogin-1 mRNA expression induced by LPS (Fig. 5A and 5B) and promoted iNos mRNA expression both with and without LPS injection (Fig. 5C and 5D).
Transcription (expression) of atrogin-1
4) Confidence 0.52 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2361191 Disease Relevance 0.14 Pain Relevance 0.03
However, when PI3K/Akt activities are low, the FoxOs are not phosphorylated, so they can enter the nucleus to increase the transcription of atrogin-1, resulting in an increase in muscle protein degradation [35–37].
Transcription (transcription) of atrogin-1 in muscle
5) Confidence 0.15 Published 2007 Journal Pediatr Nephrol Section Body Doc Link PMC2259254 Disease Relevance 0.65 Pain Relevance 0.12
When these transcription factors are phosphorylated by Akt, they cannot enter the nucleus to stimulate transcription of atrogin-1.
Transcription (transcription) of atrogin-1 in nucleus
6) Confidence 0.13 Published 2007 Journal Pediatr Nephrol Section Body Doc Link PMC2259254 Disease Relevance 0.62 Pain Relevance 0.13

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox